Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

China’s NHSA Opens NRDL to AI and Digital Health Innovation, Unveils Scenario‑Driven Reimbursement Reform

Fineline Cube Feb 6, 2026
Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Fineline Cube Feb 6, 2026
Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Fineline Cube Feb 6, 2026
Company Drug

Accuredit Therapeutics Initiates First Dosing of Gene Therapy ART001 for ATTR

Fineline Cube Oct 20, 2023

China-based gene therapy start-up Accuredit Therapeutics (Suzhou) Co., Ltd has announced the first dosing of...

Company

Bayer HealthCare Launches First Innovation Center in Beijing’s ETown

Fineline Cube Oct 20, 2023

Bayer HealthCare (ETR: BAYN) has formally inaugurated its inaugural innovation center in China, strategically situated...

Legal / IP Policy / Regulatory

China’s State Council Unveils Plan to Boost Patent Commercialization by 2025

Fineline Cube Oct 20, 2023

China’s State Council has recently approved the “Special Action Plan for Patent Commercialization and Utilization...

Company Drug

BMS’s Sotyktu Receives NMPA Approval for Psoriasis Treatment

Fineline Cube Oct 20, 2023

The National Medical Products Administration (NMPA) has granted regulatory approval to US-based pharmaceutical major Bristol-Myers...

Company Drug

CDE Grants Priority Review to Pearl Biotech’s Breatinib for Glioblastoma Treatment

Fineline Cube Oct 20, 2023

China’s Center for Drug Evaluation (CDE) has indicated that Beijing Pearl Biotechnology Co., Ltd’s breatinib...

Company

Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand

Fineline Cube Oct 20, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2023 report, indicating that a reduced...

Company Drug

BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC

Fineline Cube Oct 20, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study...

Company Deals

Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases

Fineline Cube Oct 20, 2023

Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE...

Company Deals

MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates

Fineline Cube Oct 20, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...

Company

HuidaGene Receives FDA Rare Pediatric Disease Designation for MECP2 Syndrome Therapy

Fineline Cube Oct 19, 2023

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced that it has received Rare Pediatric Disease...

Company

Kyowa Hakko Kirin Doubles Manufacturing Capacity with Shanghai Plant Expansion

Fineline Cube Oct 19, 2023

Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of...

Company Deals

Sansure Biotech Partners with Shaanxi Lifegen to Boost Molecular Diagnostics

Fineline Cube Oct 19, 2023

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with...

Company Deals

Alebund Pharmaceuticals Secures Exclusive Rights to Roche’s Mircera in China

Fineline Cube Oct 19, 2023

Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX:...

Company Drug

AstraZeneca’s Soliris Gains Approval in China for NMOSD Treatment

Fineline Cube Oct 19, 2023

UK-based pharmaceutical giant AstraZeneca Plc (AZ, NASDAQ: AZN) has announced that its rare disease drug...

Legal / IP

CNIPA Upholds Alnylam’s PCSK9-Targeted siRNA Patent Against Junshi Biosciences Challenge

Fineline Cube Oct 19, 2023

The China National Intellectual Property Administration (CNIPA) has rejected another challenge from Junshi Biosciences (SHA:...

Company Drug

Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023

Fineline Cube Oct 19, 2023

China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...

Company Drug

Guangdong Zhongsheng Launches AI Q&A Bot for Leritrelvir Drug Support

Fineline Cube Oct 19, 2023

China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced the innovative launch of a...

Company R&D

WuXi XDC Partners with Hong Kong Science Park to Boost CRDMO Value Chain

Fineline Cube Oct 19, 2023

WuXi XDC, a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary...

Company Deals

AlphaGen Therapeutics Secures Seed Funding for Pb-212 Radioligand Therapy Development

Fineline Cube Oct 19, 2023

AlphaGen Therapeutics Ltd, a Shanghai-based developer specializing in radioligand therapy (RLT), has reportedly secured “tens...

Company Drug

Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA

Fineline Cube Oct 19, 2023

Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...

Posts pagination

1 … 412 413 414 … 621

Recent updates

  • Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging
  • Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China
  • Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial
  • Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China
  • Ascentage Pharma Secures NMPA Approval for APG‑3288 BTK Degrader Trial in Hematologic Malignancies
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Company Drug

Fosun Pharma’s Fumaining Wins Priority Review for NF1 Adult Indication in China

Company Drug

Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial

Company Drug

Akeso’s Ivonescimab Secures Fifth Breakthrough Therapy Designation for Biliary Tract Cancer in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.